These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17010076)

  • 1. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
    Moeremans K; Annemans L
    Int J Gynecol Cancer; 2006; 16 Suppl 2():576-8. PubMed ID: 17010076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A; Verma S
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
    Lux MP; Wöckel A; Benedict A; Buchholz S; Kreif N; Harbeck N; Kreienberg R; Kaufmann M; Beckmann MW; Jonat W; Hadji P; Distler W; Raab G; Tesch H; Weyers G; Possinger K; Schneeweiss A
    Onkologie; 2010; 33(4):155-66. PubMed ID: 20389141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
    Mansel R; Locker G; Fallowfield L; Benedict A; Jones D
    Br J Cancer; 2007 Jul; 97(2):152-61. PubMed ID: 17622238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil.
    Fonseca M; Araújo GT; Saad ED
    Rev Assoc Med Bras (1992); 2009; 55(4):410-5. PubMed ID: 19750307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
    Simons WR; Jones D; Buzdar A
    Clin Ther; 2003 Nov; 25(11):2972-87. PubMed ID: 14693319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer].
    Gamboa O; Díaz S; Chicaíza L; García M
    Biomedica; 2010; 30(1):46-55. PubMed ID: 20890549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
    Imai H; Kuroi K; Ohsumi S; Ono M; Shimozuma K
    Breast Cancer; 2007; 14(1):81-7. PubMed ID: 17245000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G; Verma S; Trudeau M
    Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
    Lipsitz M; Delea TE; Guo A
    Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
    Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
    Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer].
    Sasse AD; Sasse EC
    Rev Assoc Med Bras (1992); 2009; 55(5):535-40. PubMed ID: 19918652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.